Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
ABSTRACT Introduction Developing a more effective treatment for the global impact of diabetic kidney disease is crucial. This study examined the renoprotective effects of combining glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) with sodium–glucose cotransporter 2 inhibitors (SGLT2i) compared t...
Saved in:
Main Authors: | Jian‐Yu Jhu, Yu‐Wei Fang, Chung‐Yen Huang, Hung‐Hsiang Liou, Mon‐Ting Chen, Ming‐Hsien Tsai |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-02-01
|
Series: | Journal of Diabetes Investigation |
Subjects: | |
Online Access: | https://doi.org/10.1111/jdi.14361 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sodium Chloride Cotransporter in Hypertension
by: Annalisa Castagna, et al.
Published: (2024-11-01) -
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
by: Kosuke Sawami, et al.
Published: (2024-11-01) -
The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure
by: M. Yu. Kolesnyk, et al.
Published: (2024-03-01) -
Assessment of the Utilization of Sodium–Glucose Cotransporter-2 Inhibitors in Patients Without Diabetes
by: Takuma Koinuma, et al.
Published: (2024-12-01) -
Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?
by: Paschalis Karakasis, et al.
Published: (2024-11-01)